Dynamic Annuloplasty System With Activation for the Treatment of Mitral Regurgitation (DYANA)
The recruitment status of this study is unknown because the information has not been verified recently.
Verified January 2009 by MiCardia Corporation.
Recruitment status was Recruiting
Recruitment status was Recruiting
Sponsor:
MiCardia Corporation
Information provided by:
MiCardia Corporation
ClinicalTrials.gov Identifier:
NCT00833014
First received: January 8, 2009
Last updated: January 29, 2009
Last verified: January 2009
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The device is a dynamic annuloplasty ring/band that is able to be adjusted in order to correct for mitral regurgitation intraoperatively or postoperatively, off-pump.
| Condition | Intervention | Phase |
|---|---|---|
|
Mitral Valve Regurgitation |
Device: Dynamic Annuloplasty Ring (with option to adjust off-pump) |
Phase 2 |
| Study Type: | Interventional |
| Study Design: | Allocation: Non-Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | Dynamic Annuloplasty System With Activation for the Treatment of Mitral Regurgitation |
Further study details as provided by MiCardia Corporation:
Primary Outcome Measures:
- Freedom from major complications and SAM (Systolic Anterior Motion) [ Time Frame: 6 months ] [ Designated as safety issue: Yes ]
Secondary Outcome Measures:
- Ability to adjust annuloplasty ring off-pump post implantation to correct for residual regurgitation, reduction of mitral valve regurgitation at follow-up visits (discharge, 30 days, 6 months) [ Time Frame: 6 months ] [ Designated as safety issue: No ]
| Estimated Enrollment: | 130 |
| Study Start Date: | December 2008 |
| Estimated Study Completion Date: | December 2010 |
| Estimated Primary Completion Date: | December 2010 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
| Experimental: I |
Device: Dynamic Annuloplasty Ring (with option to adjust off-pump)
Annuloplasty device repair of mitral valve regurgitation with option to adjust device post implant.
|
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- This patient requires mitral valve repair with or without concomitant procedures such as coronary artery bypass or another valve reconstruction or replacement.
- This patient has been diagnosed with a diseased natural valve, based on echocardiography and is a candidate for mitral valve repair.
- This patient is in satisfactory condition, based on the physical exam and investigator's experience, to be an average or better operative risk. (i.e., likely to survive one year postoperatively).
- This patient is geographically stable and willing to return to the implant center for follow-up visits.
- This patient has been adequately informed of his/her participation in the clinical study, and of what will be required of him/her, in order to comply with the protocol.
Exclusion Criteria:
- This patient is less than eighteen (18) years of age.
- This patient has a non-cardiac major or progressive disease, which in the investigator's experience produces an unacceptable increased risk to the patient, or results in a life expectancy of less than twelve months.
- This patient has an ejection fraction < 30%.
- This patient has a heavily calcified annulus or leaflets.
- This patient presents with active endocarditis or has had active endocarditis in the last 3 months.
- This patient is pregnant (urine HCG test result positive) or lactating.
- This patient is an intravenous drug abuser or alcohol abuser.
- This patient has a previously implanted prosthetic mitral valve.
- This patient requires mitral valve replacement.
- This patient has a creatinine level > 2.0 mg/dl
- This patient has had congestive heart failure within the past 6 months requiring surgical treatment.
- This patient has had a coronary artery ischemic event within the past 6 months.
- This patient has a known life threatening, non-cardiac disease that will limit the patient's life expectancy to less than one year.
- This patient is unable to take Coumadin.
- This patient has a known untreatable allergy to contrast media or nickel.
- This patient has had a cerebral vascular event within the past 6 months.
- This patient is a prisoner (U.S.A. Only).
- This patient is participating in concomitant research studies of investigational products.
- This patient will not agree to return to the implant center for the required number of follow-up visits or is geographically unavailable for follow-up.
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00833014
Contacts
| Contact: Jody L Errandi, M.S. | 949.951.4888 ext 12 | jerrandi@micardia.com |
Locations
| Canada, British Columbia | |
| University of British Columbia | Not yet recruiting |
| Vancouver, British Columbia, Canada, V6Z1Y6 | |
| Contact: Kevin Schillitto 604-806-8383 KShillitto@providencehealth.bc.ca | |
| Principal Investigator: Jian Ye, MD | |
| Germany | |
| University of Saarlands | Recruiting |
| Homburg, Germany, 66421 | |
| Contact: Frank Langer, MD 06841/1632000 frank.langer@uks.eu | |
| Principal Investigator: H J Schafers, MD, PhD | |
| Universitatsklinikum Schleswig-Holstein | Recruiting |
| Kiel, Germany, 24105 | |
| Contact: Arne M Eide, MD +1494315974400 eideam@hotmail.com | |
| Principal Investigator: Jochen Cremer, MD PhD | |
| University of Leipzig Herzzentrum | Recruiting |
| Leipzig, Germany, 04289 | |
| Contact: Sissy Ott +4903418651570 sissy.ott@herzzentrum-leipzig.de | |
| Netherlands | |
| Erasmus MC | Not yet recruiting |
| Rotterdam, Netherlands | |
| Contact: Liesbeth Duininck + 310107032150 e.duininck@erasmusmc.nl | |
| Principal Investigator: Pieter Kappetein, MD PhD | |
Sponsors and Collaborators
MiCardia Corporation
More Information
Additional Information:
Related Info 
Publications:
| Responsible Party: | Paul Molloy, CEO, MiCardia Corporation |
| ClinicalTrials.gov Identifier: | NCT00833014 History of Changes |
| Other Study ID Numbers: | TP07-006 |
| Study First Received: | January 8, 2009 |
| Last Updated: | January 29, 2009 |
| Health Authority: | EU: KEMA |
Additional relevant MeSH terms:
|
Mitral Valve Insufficiency Heart Valve Diseases Heart Diseases Cardiovascular Diseases |
ClinicalTrials.gov processed this record on May 16, 2013